EMA Authorised: Natpar (parathyroid hormone) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

EU authorises Natpar (parathyroid hormone) for hypoparathyroidism. The decision includes conditional approval and orphan medicine designation for Takeda Pharmac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• Natpar (parathyroid hormone)

Snippet

Status: Authorised. Therapeutic area: Hypoparathyroidism. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 11/07/2025. Conditional approval. Orphan medicine